Publications
303
Citations
7,540
Est. group size
—
Recurring co-author estimate
Active years
54
Publishing since 1973
Stephanie V. Blank works in gynecologic oncology, focusing on the diagnosis, treatment, and management of ovarian, endometrial, and cervical cancers. Her recent work covers clinical trials of drug therapies, screening and detection methods, cost-effectiveness of treatment strategies, risk-reduction surgeries for hereditary cancer risk (including BRCA mutation carriers), and disparities in cancer care access.
Publication output has fluctuated over the past decade but shows an overall increasing trend, rising from about 19 papers/year in 2017 to a peak of 32 in 2024, with a mean of roughly 18 publications per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Tisotumab vedotin–associated Stevens–Johnson syndrome in a patient with recurrent vulvar cancer: Vulnerability and antibody drug conjugate toxicity considerations
Gynecologic Oncology Reports · 2026
- Impact of organ-adjacent extracellular vesicle proteomics from uterine lavage on accurate detection and discrimination of ovarian cancer.
Journal of Clinical Oncology · 2026
- Performance of ultrasound and rates of guideline-concordant care in a diverse postmenopausal bleeding cohort
American Journal of Obstetrics and Gynecology · 2025
- Validation of an Administrative Claims-based Line of Therapy Algorithm for Women with Ovarian Cancer Using Medical Chart Review
Advances in Therapy · 2025
- Cervical cancer in women under age 40: A cohort study of clinicopathological characteristics and fertility-sparing surgery outcomes
Gynecologic Oncology Reports · 2025
- Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer
Gynecologic Oncology · 2025
- Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution
American Journal of Obstetrics and Gynecology · 2025
- Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Gynecologic Oncology · 2025
- NTM-Infektion: Erregerwechsel im MAC- Komplex nach erfolgreicher Eradikation
Pneumologie · 2025
- Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy
Obstetrical & Gynecological Survey · 2025
- Epidemiology and Outcomes of Patients With Adult Congenital Heart Disease in Queensland Intensive Care Units: A Multicentre Retrospective Observational Study
Heart Lung and Circulation · 2025
- Cost-Effectiveness of Biomarker-Based and Universal Strategies for the Treatment of Advanced Stage Endometrial Cancer
SSRN Electronic Journal · 2025
- Surveillance Visits for Ovarian Cancer: Is It Time to Reconsider?
Journal of Surgical Oncology · 2025
- Disparities in emergency department utilization among patients diagnosed with endometrial cancer
Gynecologic Oncology · 2025
- Supply outpacing demand: Trends and geographic distribution of gynecologic oncology fellowship programs
Gynecologic Oncology · 2025
- Gynecologic Oncology×80
- Journal of Clinical Oncology×15
- Gynecologic Oncology Reports×7
- American Journal of Obstetrics and Gynecology×5
- International Journal of Gynecological Cancer×5
- Monica Levine
Medicine · The Ohio State University
- David M. O’Malley
Medicine · The Ohio State University
- Larry J. Copeland
Medicine · The Ohio State University
- Laura Chambers
Medicine · The Ohio State University
- John Wallbillich
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile